United Therapeutics CORP Form 4 insider transactions

Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp., executed a series of stock option exercises and sales under a pre-arranged 10b5-1 trading plan.

United Therapeutics Chairperson & CEO Martine A. Rothblatt reported transactions involving the exercise of stock options and the sale of common stock, executed under a pre-arranged 10b5-1 trading plan.

Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp, reported a series of stock transactions on July 2, 2026, involving the exercise of stock options and subsequent sale of common stock.

Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp, reported transactions involving the exercise of stock options and sale of common stock under a pre-arranged 10b5-1 trading plan.

Martine A. Rothblatt, Chairperson & CEO of United Therapeutics, reported a series of transactions involving the exercise of stock options and the sale of common stock on June 29, 2026.

Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp, reported transactions involving the acquisition and disposition of common stock on June 26, 2026, under a Rule 10b5-1 trading plan.

Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp, reported transactions involving the acquisition and disposition of common stock on June 25, 2026, under a Rule 10b5-1 trading plan.

Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp., reported transactions involving the exercise of stock options and sale of common stock on June 24, 2026, under a pre-arranged 10b5-1 trading plan.

Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp, reported significant stock transactions on June 23, 2026, involving option exercises and stock sales under a 10b5-1 plan.

Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp., reported transactions involving common stock and stock options on June 22, 2026, executed under a 10b5-1 trading plan.

Paul A. Mahon, EVP & General Counsel of United Therapeutics Corp, reported transactions involving the exercise of stock options and sale of common stock.

Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp., reported transactions involving the sale of common stock acquired through stock option exercises, executed under a pre-arranged 10b5-1 trading plan.

Chairperson and CEO Martine Rothblatt exercised 9,500 stock options and sold the resulting shares under a 10b5-1 plan.

Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp, reported transactions involving the exercise of stock options and sale of common stock under a pre-arranged 10b5-1 trading plan.

United Therapeutics Corp. CFO and Treasurer James Edgemond reported the sale of 10,000 shares of common stock, acquired through stock options, as part of a pre-arranged 10b5-1 trading plan.

Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp., reported a series of transactions involving the exercise of stock options and the sale of common stock on June 12, 2026, executed under a Rule 10b5-1 trading plan.

CFO James Edgemond exercised 10,000 stock options and sold the resulting shares under a pre-established Rule 10b5-1 trading plan.

CEO Martine Rothblatt exercised 9,500 stock options and sold the resulting shares under a pre-arranged 10b5-1 trading plan.

CEO Martine Rothblatt exercised 9,500 stock options and sold the resulting shares under a pre-arranged 10b5-1 trading plan.

United Therapeutics Chairperson & CEO Martine A. Rothblatt reported transactions involving the exercise of stock options and sale of common stock under a pre-arranged 10b5-1 trading plan.

CFO James Edgemond exercised 10,000 stock options and sold the resulting shares under a pre-arranged 10b5-1 trading plan.

CEO Martine Rothblatt exercised 9,500 stock options and sold the resulting shares under a pre-arranged 10b5-1 trading plan.

United Therapeutics Chairperson & CEO Martine A. Rothblatt executed a series of stock option exercises and sales on June 5, 2026, under a pre-arranged 10b5-1 trading plan.

CFO James Edgemond exercised 10,000 stock options and sold the resulting shares under a pre-established Rule 10b5-1 trading plan.

EVP and General Counsel Paul A. Mahon exercised 8,300 stock options and sold the resulting shares under a 10b5-1 trading plan.

Martine A. Rothblatt, Chairperson & CEO of United Therapeutics, reported transactions involving the exercise of stock options and sale of common stock under a pre-arranged 10b5-1 trading plan.

Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp, reported transactions involving the exercise of stock options and sale of common stock under a pre-arranged 10b5-1 trading plan.

James Edgemond, CFO and Treasurer of United Therapeutics Corp., reported transactions involving the exercise of stock options and sale of common stock under a pre-arranged 10b5-1 trading plan.

Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp., has sold 1,500 shares of common stock as part of a pre-arranged 10b5-1 trading plan.

Martine A. Rothblatt, Chairperson & CEO of United Therapeutics Corp., reported transactions involving the sale of common stock acquired through stock option exercises, executed under a pre-arranged trading plan.